Modavar Pharmaceuticals

What Modavar Pharmaceuticals does

Modavar Pharmaceuticals, LLC is a vertically integrated specialty pharmaceutical company that develops, manufactures, and markets FDA-approved generic prescription pharmaceutical products. Founded in 2005 and headquartered in Washington, D.C., the company is a wholly-owned subsidiary of Cadila Pharmaceuticals, Ltd., India's largest privately-owned pharmaceutical company. Modavar maintains a portfolio of 23 FDA-approved products spanning multiple therapeutic categories — NSAIDs (Celecoxib), antidepressants (Fluoxetine, Paroxetine ER), antipsychotics (Olanzapine), antidiabetics (Glyburide, Nateglinide), antihypertensives (Hydralazine, Telmisartan, Nebivolol), cardiovascular agents (Sildenafil), hematinics (Folic Acid), antivirals (Acyclovir), and specialty categories such as estrogen agonists/antagonists (Raloxifene) and acetylcholinesterase inhibitors (Rivastigmine). The portfolio is AB-rated to brand references including Celebrex, Prozac, Zyprexa, Bystolic, Paxil CR, Micardis, Viagra, Starlix, Evista, Exelon, Zovirax, and Micronase.

The company's core technical capability is formulation development — specifically ANDA formulation development (with end-to-end processes including laboratory-scale optimization, Quality by Design, QMS, and analytical method development), topical and semi-solid formulations, 505(b)(2) novel products, and oral titration technology (with multiple provisional patents filed). Manufacturing is distributed across a U.S. facility in Frederick, Maryland (focused on topical products, controlled substances, and hormone-based products) and Cadila's 100-acre formulation plant in Dholka, Gujarat, India. International regulatory approvals span the U.S. FDA, WHO Geneva, UK MHRA, TGA Australia, MCC South Africa, and ANVISA Brazil. R&D draws on Cadila's 105,000+ sq. ft. facility staffed by 300+ scientists.

Modavar operates a sales-led B2B model, distributing finished products through the U.S.'s three major pharmaceutical wholesalers (AmerisourceBergen, Cardinal Health, McKesson) plus Morris & Dickson, with Eversana serving as 3PL partner. A secondary contract manufacturing business provides solid, topical, and liquid dosage form production services to pharmaceutical companies in the U.S. and European markets. Customer segments are healthcare providers and pharmacies (primary) and contract manufacturing clients (secondary). Specific product pricing is not publicly disclosed and is negotiated within standard wholesale distribution channels. The company maintains a pipeline of 9 filed ANDAs and 7 ANDA projects in development, and executed three product launches in 2023 (Acyclovir Capsules, Paroxetine ER, Telmisartan).

Name

Modavar Pharmaceuticals

Legal name

Modavar Pharmaceuticals, LLC

Website

https://modavar.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Modavar Pharmaceuticals is a vertically integrated U.S. specialty pharmaceutical company (founded 2005, subsidiary of India's Cadila Pharmaceuticals) that develops, manufactures, and markets 23 FDA-approved generic prescription drugs across therapeutic categories through major U.S. wholesalers to pharmacies and healthcare providers.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Generic pharmaceuticals
• Contract manufacturing
• ANDA development
• Topical formulations
• FDA-approved generics

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Revenue is generated through the sale of FDA-approved generic prescription pharmaceutical products. Products are distributed through major pharmaceutical wholesalers and healthcare channels. The company markets generic versions of brand-name drugs including Celebrex, Prozac, Zyprexa, Bystolic, and others.
2. Contract Manufacturing Services: Provides comprehensive contract manufacturing services including acquisition of raw materials, production, packaging and quality testing for solid, topicals and liquids dosage forms for pharmaceutical companies in the USA and European markets.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels2 records

Core offering

Modavar Pharmaceuticals develops, manufactures, and markets FDA-approved generic prescription pharmaceutical products across multiple therapeutic categories. The company offers 23 FDA-approved products with 9 filed ANDAs and 7 additional products in development pipeline. Beyond finished dosage products, Modavar provides contract manufacturing services for solid, topical, and liquid dosage forms, as well as ANDA and 505(b)(2) formulation development services for other pharmaceutical companies in the U.S. and European markets.

Product overview

Modavar Pharmaceuticals is a vertically integrated specialty pharmaceutical company that develops, manufactures, and markets generic prescription pharmaceutical products. The company offers a portfolio of FDA-approved generic drugs across multiple therapeutic categories including NSAIDs (Celecoxib), antidepressants (Fluoxetine, Paroxetine ER), antipsychotics (Olanzapine), antidiabetics (Glyburide, Nateglinide), antihypertensives (Nebivolol, Hydralazine, Telmisartan), cardiovascular agents (Sildenafil), hematinics (Folic Acid), and antivirals (Acyclovir). The product portfolio also includes specialty products like Raloxifene (Estrogen Agonist/Antagonist) and Rivastigmine (Acetylcholinesterase Inhibitor). Beyond finished dosage products, Modavar provides contract manufacturing services for solid, topical, and liquid dosage forms, as well as ANDA and 505(b)(2) formulation development services through its FDA-approved Frederick, Maryland facility and Cadila Pharmaceuticals partnership. The company has 23 FDA-approved products with 9 filed ANDAs and 7 ANDA projects in development pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Celecoxib Capsules

Quantifiable outcome

• 23 FDA-approved products with 9 filed ANDAs and 7 more in pipeline
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Cadila Pharmaceuticals, Ltd.coreStrategic or Co-development PartnerCadila Pharmaceuticals, Ltd. (India) is the parent company of Modavar Pharmaceuticals. Cadila is the largest privately-owned pharmaceutical company in India. The partnership provides Modavar access to extensive R&D facilities (105,000+ sq. ft., 300+ scientists), formulation development capabilities, ANDA development support, and manufacturing capacity. Cadila operates a 100-acre formulation plant in Dholka, Gujarat, India with multiple global regulatory approvals.
• EversanacoreChannel Partner/ Reseller/ DistributorPremier 3PL (third-party logistics) provider used by Modavar for all supply chain management needs. Eversana handles distribution and logistics for pharmaceutical products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Glenmark Pharmaceuticals: Indian-headquartered specialty generic pharmaceutical company with significant US operations and similar therapeutic breadth across CNS, cardiovascular, and other areas. Comparable vertically-integrated model with US distribution relationships and similar ANDA-driven product launches.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with substantial US operations. Comparable AB-rated generic product portfolio, vertically integrated manufacturing, and contract development capabilities across multiple dosage forms.
• Endo International: US-based specialty and generic pharmaceutical company. Comparable portfolio of generic and specialty pharmaceutical products with focus on differentiated formulations and similar therapeutic area coverage including CNS and cardiovascular.
• Aurobindo Pharma: Indian generic pharmaceutical company with vertically integrated operations and substantial US market presence. Comparable ANDA pipeline approach and contract manufacturing capabilities for solid, injectable, and topical dosage forms distributed through US wholesalers.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with significant US generic business. Comparable integrated operations with ANDA pipeline, multiple dosage form capabilities, and distribution through US wholesalers. Therapeutic areas overlap on CNS, cardiovascular, and diabetes products.
• Lupin Pharmaceuticals: Indian generic pharmaceutical manufacturer with strong US presence focused on oral solids and specialty formulations. Similar business model of developing and marketing AB-rated generic products in the US through major wholesalers with comparable ANDA pipeline approach.
• Lannett Company: US-focused generic pharmaceutical manufacturer specializing in oral solid, topical, and liquid generic products. Comparable size and product portfolio approach with focus on AB-rated generics distributed through major US wholesalers.
• Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical company with India manufacturing operations. Highly comparable business model combining AB-rated generics with specialty 505(b)(2) product development and similar therapeutic area breadth across CNS, cardiovascular, and other areas.

Broad incumbents

• Teva Pharmaceutical Industries: Largest generic pharmaceutical manufacturer globally with extensive US operations and broad portfolio across all therapeutic areas. While much larger than Modavar, competes in the same generic pharmaceutical space with overlapping AB-rated product offerings including CNS, cardiovascular, and antiviral categories.
• Sandoz: Generic pharmaceuticals division of Novartis with global operations including significant US presence. Comparable product portfolio in AB-rated generics and contract manufacturing, though at much larger scale, with overlapping therapeutic area coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modavar Pharmaceuticals